MedTrace Logo

Study to Test the Efficacy and Safety of Vafidemstat in Adult Borderline Personality Disorder Population

NCT04932291 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 211

Last updated 2026-05-05

Study results available
· View outcomes & findings →

Summary

PORTICO is a Phase IIb study to evaluate the efficacy and safety of vafidemstat in an adult borderline personality disorder (BPD) population.

Conditions

  • Borderline Personality Disorder

Interventions

DRUG

vafidemstat

1.2mg capsule

DRUG

Placebo

placebo capsule

Sponsors & Collaborators

  • Oryzon Genomics S.A.

    lead INDUSTRY

Principal Investigators

  • Michael Ropacki, MD · Oryzon Genomics

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-26
Primary Completion
2023-10-30
Completion
2023-11-13
FDA Drug
Yes

Countries

  • United States
  • Bulgaria
  • Germany
  • Serbia
  • Spain

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04932291 on ClinicalTrials.gov